Presentation 10-Year Clinical Outcome After Randomization to Sirolimus- or Paclitaxel-Eluting Coronary stents February 13, 2017 REGISTER for free or LOG IN to view this content Coronary ACS/AMI CAD Pharma DES/BRS/DCB Factoid Up Next Presentation Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents February 13, 2017 More slides + Presentation Everolimus-Eluting Versus Novolimus-Eluting Bioresorbable Scaffolds for CAD Presenter: Jens Wiebe February 16, 0017 Presentation Mitral Valve 2017 Prognosis of Tricuspid Regurgitation in the Era of Transcatheter Interventions Presenter: Thomas Modine February 07, 2017 We Recommend
Presentation Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents February 13, 2017
Presentation Everolimus-Eluting Versus Novolimus-Eluting Bioresorbable Scaffolds for CAD Presenter: Jens Wiebe February 16, 0017
Presentation Mitral Valve 2017 Prognosis of Tricuspid Regurgitation in the Era of Transcatheter Interventions Presenter: Thomas Modine February 07, 2017